What is the share price of Sanofi India Ltd (SANOFI) today?
The share price of SANOFI as on 15th September 2026 is ₹3131. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Sanofi India Ltd (SANOFI) share?
The past returns of Sanofi India Ltd (SANOFI) share are- Past 1 week: 0.24%
- Past 1 month: -3.07%
- Past 3 months: -3.39%
- Past 6 months: -8.93%
- Past 1 year: -37.87%
- Past 3 years: -56.40%
- Past 5 years: -61.43%
What are the peers or stocks similar to Sanofi India Ltd (SANOFI)?
The peers or stocks similar to Sanofi India Ltd (SANOFI) include:What is the dividend yield % of Sanofi India Ltd (SANOFI) share?
The current dividend yield of Sanofi India Ltd (SANOFI) is 3.93.What is the market cap of Sanofi India Ltd (SANOFI) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sanofi India Ltd (SANOFI) is ₹7210.89 Cr as of 15th September 2026.What is the 52 week high and low of Sanofi India Ltd (SANOFI) share?
The 52-week high of Sanofi India Ltd (SANOFI) is ₹5107.50 and the 52-week low is ₹3054.What is the PE and PB ratio of Sanofi India Ltd (SANOFI) stock?
The P/E (price-to-earnings) ratio of Sanofi India Ltd (SANOFI) is 22.07. The P/B (price-to-book) ratio is 9.62.Which sector does Sanofi India Ltd (SANOFI) belong to?
Sanofi India Ltd (SANOFI) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Sanofi India Ltd (SANOFI) shares?
You can directly buy Sanofi India Ltd (SANOFI) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Sanofi India Ltd
SANOFI Share Price
NSE₹3,131.001.68% (+51.80)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SANOFI Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SANOFI Performance & Key Metrics
SANOFI Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 22.27 | 9.62 | 3.93% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.37 | 5.81 | 0.49% |
100%
Analysts have suggested that investors can buy this stock
from 2 analysts
Price Upside
Earnings Growth
Rev. Growth
SANOFI Company Profile
Sanofi India Limited is engaged in the manufacture and sale of pharmaceutical products.
SUNPHARMA
PE Ratio
38.35
38.35
1Y Return
14.54%
14.54%
Buy Reco %
93.55
93.55
TORNTPHARM
PE Ratio
85.27
85.27
1Y Return
37.33%
37.33%
Buy Reco %
81.48
81.48
ZYDUSLIFE
PE Ratio
21.75
21.75
1Y Return
5.99%
5.99%
Buy Reco %
57.69
57.69
CIPLA
PE Ratio
28.13
28.13
1Y Return
12.74%
12.74%
Buy Reco %
62.86
62.86
LAURUSLABS
PE Ratio
117.14
117.14
1Y Return
115.30%
115.30%
Buy Reco %
58.33
58.33
SANOFI Sentiment Analysis
SANOFI Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SANOFI Stock Summary · August 2026
Management presented a picture of solid diabetes-led growth alongside disciplined cost control and a cautious view on some non-core businesses. Diabetes remained the main engine, with Q2 growth of around 14% and H1 growth of 17%, supported by Toujeo, Soliqua and the broader insulin franchise, while the company said it remains the basal analog market leader and expects the segment to outgrow the market. Management also stressed that public-sector expansion and stronger Indian real-world evidence are helping widen access and reinforce product positioning, particularly in tier-two and tier-three markets. At the same time, the partnership portfolio was described as distorted by prior-year inventory and return effects, with Q2 growth of 2% below expectations and management saying 2027 is a more realistic inflection point. Profitability improved, with PBT and exceptional items up 19% to INR 112 crores and PBT margin rising to 27%, while cash grew 34%. Looking ahead, management said exports remain under pressure, buybacks are not part of current strategy, and diabetes should continue to lead growth, with 2026 viewed as an acceleration year.
SANOFI Stock Growth Drivers
SANOFI Stock Growth Drivers
9Diabetes Franchise Momentum and Market Leadership
The company’s diabetes business showed strong and sustained momentum, with growth of about 14% in
Evidence-Led Product Strength and Guideline Support
Sanofi India strengthened the positioning of Toujeo and Soliqua through Indian real-world evidence, patient data,
SANOFI Stock Challenges
SANOFI Stock Challenges
4Partnership Transition and Comparison Drag on Reported Growth
Reported performance has been weighed down by transition-related and prior-year one-off effects in the partnership
Weak Export Performance and Consumer Health Income Pressure
Export remains a persistent weak spot, with year-to-date sales and volumes under pressure and export-related
SANOFI Forecast
SANOFI Forecasts
Price
Revenue
Earnings
SANOFI Share Price Forecast
SANOFI Share Price Forecast
2026
Current
₹3,131.00
Baseline
Forecast for Sep 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹3,131.00
Baseline
Forecast for Sep 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
SANOFI Company Revenue Forecast
SANOFI Company Revenue Forecast
2025
Current
₹1.86
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹1.86
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
SANOFI Stock EPS (Earnings Per Share) Forecast
SANOFI Stock EPS (Earnings Per Share) Forecast
2025
Current
₹141.85
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹141.85
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
SANOFI
SANOFI
Income
Balance Sheet
Cash Flow
Quarterly Normal View
SANOFI Income Statement
SANOFI Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 578.90 | 503.50 | 526.30 | 528.80 | 539.20 | 415.00 | 480.30 | 422.60 | 476.70 | 443.90 | ||||||||||
Operating & Other expenses | 400.40 | 366.80 | 404.30 | 396.60 | 364.00 | 311.40 | 368.50 | 329.50 | 329.50 | 322.40 | ||||||||||
EBITDA | 178.50 | 136.70 | 122.00 | 132.20 | 175.20 | 103.60 | 111.80 | 93.10 | 147.20 | 121.50 | ||||||||||
| Depreciation/Amortization | 9.10 | 9.00 | 9.00 | 9.60 | 9.60 | 9.10 | 9.10 | 9.50 | 9.00 | 8.90 | ||||||||||
| PBIT | 169.40 | 127.70 | 113.00 | 122.60 | 165.60 | 94.50 | 102.70 | 83.60 | 138.20 | 112.60 | ||||||||||
| Interest & Other Items | 0.30 | 0.40 | 0.40 | 0.40 | 0.30 | 0.40 | 0.40 | 0.60 | 0.30 | 0.30 | ||||||||||
| PBT | 169.10 | 127.30 | 112.60 | 122.20 | 165.30 | 94.10 | 102.30 | 83.00 | 137.90 | 112.30 | ||||||||||
| Taxes & Other Items | 32.50 | 23.90 | 30.40 | 30.90 | 45.80 | 24.60 | 26.30 | 21.30 | 35.30 | 28.80 | ||||||||||
| Net Income | 136.60 | 103.40 | 82.20 | 91.30 | 119.50 | 69.50 | 76.00 | 61.70 | 102.60 | 83.50 | ||||||||||
| EPS | 59.31 | 44.90 | 35.69 | 39.64 | 51.89 | 30.18 | 32.99 | 26.79 | 44.55 | 36.26 |
SANOFI Company Updates
FY 2026FY 2026
Investor Presentation
Feb 26PDF
Oct 29PDF
SANOFI Stock Peers
SANOFI Past Performance & Peer Comparison
SANOFI Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sanofi India Ltd | 22.07 | 9.62 | 3.93% |
| Sun Pharmaceutical Industries Ltd | 38.35 | 5.25 | 0.87% |
| Torrent Pharmaceuticals Ltd | 85.27 | 10.49 | 0.70% |
| Zydus Lifesciences Ltd | 21.75 | 3.71 | 0.09% |
SANOFI Stock Price Comparison
Compare SANOFI with any stock or ETFCompare SANOFI with any stock or ETF
SANOFI
SANOFI Holdings
SANOFI Shareholdings
SANOFI Promoter Holdings Trend
SANOFI Promoter Holdings Trend
SANOFI Institutional Holdings Trend
SANOFI Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 1.19%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SANOFI Shareholding Pattern
SANOFI Shareholding Pattern
SANOFI Shareholding History
SANOFI Shareholding History
Foreign Institutions
Mutual Funds Invested in SANOFI
Mutual Funds Invested in SANOFI
No mutual funds holding trends are available
Top 5 Mutual Funds holding Sanofi India Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.1140% | Percentage of the fund’s portfolio invested in the stock 0.18% | Change in the portfolio weight of the stock over the last 3 months -0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 114/271 (+53) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.4994% | Percentage of the fund’s portfolio invested in the stock 0.36% | Change in the portfolio weight of the stock over the last 3 months 0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 36/84 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2949% | Percentage of the fund’s portfolio invested in the stock 0.99% | Change in the portfolio weight of the stock over the last 3 months 0.12% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 32/39 (0) |
Compare 3-month MF holding change on Screener
smallcases containing SANOFI stock
smallcases containing SANOFI stock
Looks like this stock is not in any smallcase yet.
SANOFI Events
SANOFI Events
SANOFI Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SANOFI has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 3.67%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹36.69 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SANOFI Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SANOFI has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 3.67%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹36.69 every year
SANOFI Upcoming Dividends
SANOFI Upcoming Dividends
No upcoming dividends are available
SANOFI Past Dividends
SANOFI Past Dividends
Cash Dividend
Ex DateEx DateApr 22, 2026
Final
Final | Div/Share: ₹48.00
Dividend/Share
₹48.00
Ex DateEx Date
Apr 22, 2026
Cash Dividend
Ex DateEx DateNov 7, 2025
Interim
Interim | Div/Share: ₹75.00
Dividend/Share
₹75.00
Ex DateEx Date
Nov 7, 2025
Cash Dividend
Ex DateEx DateApr 25, 2025
Final
Final | Div/Share: ₹117.00
Dividend/Share
₹117.00
Ex DateEx Date
Apr 25, 2025
Cash Dividend
Ex DateEx DateMay 3, 2024
Final
Final | Div/Share: ₹117.00
Dividend/Share
₹117.00
Ex DateEx Date
May 3, 2024
Cash Dividend
Ex DateEx DateMar 7, 2024
Interim
Interim | Div/Share: ₹50.00
Dividend/Share
₹50.00
Ex DateEx Date
Mar 7, 2024
SANOFI Stock News & Opinions
SANOFI Stock News & Opinions
Articles & Videos
Corporate
Corporate
Sanofi India’s net profit dipped slightly to Rs 1,861 million for the first half of 2026Sanofi India Limited reported a net profit of Rs 1,861 million for the half-year ended June 30, 2026, a slight decrease from Rs 1,890 million in the same period last year. While the company’s profit before tax declined by Rs 92 million, representing a 3.56% decrease, the company’s total assets increased to Rs 14,074 million from Rs 12,548 million. The company’s total equity also rose to Rs 8,260 million from Rs 7,492 million. Sanofi India experienced a net cash inflow of Rs 2,114 million from operating activities and a net increase in cash and cash equivalents of Rs 961 million, alongside a substantial dividend payment. The increase in trade receivables and inventory warrants further monitoring, and a prior year personnel separation cost of Rs 273 million impacted previous results.
1 month agoCapital Market - Live
Corporate
Corporate
Sanofi India's Nakul Verma to transition to another role within the group by July 2026Sanofi India Limited announced that Mr. Nakul Verma, Head of Public Affairs & Market Access, will cease to be a Senior Management Personnel with effect from the close of business hours on 31st July 2026, due to a transition to another role within the Sanofi group.
1 month agoCapital Market - Live
Spotlight
Spotlight
Sanofi India CFO Rachid Ayari to step down from key roles effective 30 Sept 2026The company said Ayari has decided to relinquish his current responsibilities following his transition to another role within the Sanofi group. Following his cessation, Ayari will no longer serve as Whole Time Director, CFO, KMP, Senior Management Personnel, or a member of the Risk Management Committee of the company. Sanofi India expressed its appreciation for Ayari's contributions, expert guidance, and support during his tenure with the company. The company is currently in the process of identifying a suitable candidate for the position of Chief Financial Officer, who will also be appointed as a Key Managerial Personnel. The company will make an announcement regarding the appointment in due course. Sanofi India is engaged in the manufacture and marketing of pharmaceutical products and vaccines. On a standalone basis, Sanofi India's net profit declined 14.14% to Rs 102.60 crore while net sales declined 11.87% to Rs 472.30 crore in Q4 March 2026 over Q4 March 2025. The scrip shed 0.33% to Rs 3,392.40 on the BSE. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Corporate
Sanofi India to announce Quarterly ResultSanofi India will hold a meeting of the Board of Directors of the Company on 4 August 2026.
1 month agoCapital Market - Live
Spotlight
Spotlight
Sanofi India jumps after Nippon India MF adds stakeAccording to exchange data, Nippon India Mutual Fund purchased 2.64 lakh shares, or 1.15% equity, of Sanofi India at Rs 3,150 per share through a bulk deal on 12 June 2026. The shares were sold by HDFC Life Insurance Company, which offloaded 2.75 lakh shares, or 1.19% equity, at the same price. As of the March 2026 quarter, Nippon India Small Cap Fund held an aggregate 3.79% stake in Sanofi India, while HDFC Life Insurance Company's Shareholders Solvency Margin Account owned 1.47% of the pharmaceutical company. Sanofi India is engaged in the manufacture and marketing of pharmaceutical products and vaccines. On a standalone basis, Sanofi India's net profit declined 14.14% to Rs 102.60 crore while net sales declined 11.87% to Rs 472.30 crore in Q4 March 2026 over Q4 March 2025. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Sanofi India appoints senior management personnelSanofi India announced the appointment of Debajit Roy as Sales & Customer Engagement Head ' Diabetes, designated as Senior Management Personnel of the Company with effect from 8 June 2026.
3 months agoCapital Market - Live
Earnings
Earnings
Sanofi India standalone net profit declines 14.14% in the March 2026 quarterNet profit of Sanofi India declined 14.14% to Rs 102.60 crore in the quarter ended March 2026 as against Rs 119.50 crore during the previous quarter ended March 2025. Sales declined 11.87% to Rs 472.30 crore in the quarter ended March 2026 as against Rs 535.90 crore during the previous quarter ended March 2025. ParticularsQuarter EndedMar. 2026Mar. 2025% Var. Sales472.30535.90 -12 OPM %30.2432.08 - PBDT146.90174.90 -16 PBT137.90165.30 -17 NP102.60119.50 -14 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Corporate
Sanofi India announces board meeting dateSanofi India will hold a meeting of the Board of Directors of the Company on 28 April 2026.
4 months agoCapital Market - Live
Corporate
Corporate
Sanofi India to convene AGMSanofi India announced that the 70th Annual General Meeting(AGM) of the company will be held on 29 April 2026.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Corporate
Board of Sanofi India recommends final dividendSanofi India announced that the Board of Directors of the Company at its meeting held on 25 February 2026, inter alia, have recommended the final dividend of Rs 48 per equity Share (i.e. 480%) , subject to the approval of the shareholders.Powered by Capital Market - Live
6 months agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant